Searched for: subject%3A%22protein%255C+aggregation%22
(1 - 3 of 3)
document
Neves Sao Pedro, M. (author), Eppink, Michel H.M. (author), Ottens, M. (author)
The lack of process analytical technologies able to provide real-time information and process control over a biopharmaceutical process has long impaired the transition to continuous biomanufacturing. For the monoclonal antibody (mAb) production, aggregate formation is a major critical quality attribute (CQA) with several known process...
journal article 2023
document
Neves Sao Pedro, M. (author), Silva dos Santos, M. (author), Eppink, Michel H.M. (author), Ottens, M. (author)
A major challenge in the transition to continuous biomanufacturing is the lack of process analytical technology (PAT) tools which are able to collect real-time information on the process and elicit a response to facilitate control. One of the critical quality attributes (CQAs) of interest during monoclonal antibodies production is aggregate...
journal article 2022
document
Neves Sao Pedro, M. (author), Klijn, M.E. (author), Eppink, Michel H.M. (author), Ottens, M. (author)
The transition to continuous biomanufacturing is considered the next step to reduce costs and improve process robustness in the biopharmaceutical industry, while also improving productivity and product quality. The platform production process for monoclonal antibodies (mAbs) is eligible for continuous processing to lower manufacturing costs...
review 2021